The most expensive part of building a new biological product isn't writing the DNA. It's the years of lab work spent figuring out how to purify the resulting proteins at industrial scale. This downstream processing (DSP) phase is where promising fermentation-based startups often stall, burning cash on iterative physical experiments. New Wave Biotech, a London-based startup founded in 2022, is betting that a software-first approach can compress that timeline. Its core product is an AI-driven simulation platform that models purification workflows, runs virtual experiments, and suggests optimal configurations before a single milliliter hits a bioreactor [New Wave Biotech, retrieved 2026].
A wedge in downstream processing
New Wave's focus is deliberately narrow. While many bioprocess software tools address upstream fermentation, the company targets the purification and separation steps that come after. This is a high-stakes, multi-step bottleneck involving chromatography, filtration, and concentration. The platform, branded as Bioprocess Foresight, uses computational modeling and machine learning to simulate these operations. It integrates techno-economic analysis and life cycle assessment, providing a decision-support layer meant to guide R&D teams toward the most scalable and cost-effective process design [New Wave Biotech, retrieved 2026]. The value proposition is straightforward: reduce the number of costly, time-consuming wet-lab experiments required to reach a commercially viable production recipe.
The traction case and early backers
The company's most cited proof point is a claim of dramatically reducing experimental load. In promotional materials and partner case studies, New Wave states its technology has delivered an 8.6x improvement in yields and a 55% reduction in unit costs, while requiring 92% fewer experiments to reach optimized conditions [Green Queen, retrieved 2026]. These figures, while not independently audited in the public record, form the core of its pitch to the alternative protein and sustainable biochemical markets. To fund its development, New Wave has raised approximately €1.2 million (estimated $1.26 million) in a seed round closed in December 2024 [EU-Startups, Dec 2024]. The round adds to earlier grant funding, bringing total disclosed capital to around $1.32 million [Tracxn, retrieved 2026]. Its investor base is a mix of mission-aligned funds and public bodies, including EIT Food, Big Idea Ventures, and Innovate UK, which also provided non-dilutive grant support [Crunchbase, Oct 2024].
2024 Grant | 216309 | USD
2024 Seed | 1260000 | USD
The technical breakdown
At its core, the platform is a specialized digital twin for biomanufacturing. It appears to work by ingesting biochemical parameters and process constraints, then running Monte Carlo-style simulations across a defined design space. The machine learning component likely trains on both proprietary and customer-generated data to predict outcomes like yield, purity, and cost under various scenarios. The integrated techno-economic analysis is a critical feature, allowing teams to model not just scientific feasibility but commercial viability from the earliest stages of process development. This moves optimization from a purely empirical, trial-and-error domain into a guided, computational one.
Where the model could face friction
The ambition is clear, but scaling a deep-tech SaaS tool in biomanufacturing introduces specific challenges. The primary risk is data dependency. The accuracy and utility of the simulations are contingent on high-quality, relevant input data and robust underlying physicochemical models. If the platform's predictions deviate from real-world outcomes, user trust and retention would suffer quickly. Furthermore, the sales motion is inherently complex. The buyer is a cross-functional team of process engineers, scientists, and business unit leaders, each with different success metrics. Convincing them to adopt a software-driven workflow represents a significant change management hurdle.
- Validation at scale. The published performance claims (92% fewer experiments) are compelling but stem from early partner projects. The true test will be replicating these results across a diverse portfolio of molecules and production scales with new, unaffiliated customers.
- Competitive landscape. While no direct competitors are named in sources, the broader field of bioprocess modeling and simulation is not empty. Established chemical engineering software giants and niche academic spin-offs operate in adjacent spaces. New Wave's differentiation rests on its specific focus on fermentation DSP and its integrated business-case analysis.
- Team execution. Public details on the technical team are sparse. Co-founder and CEO Zoe Yu Tung Law is the public face, with CTO Oli Hall noted in some profiles [The Org, retrieved 2026]. The company is actively hiring backend and full-stack developers, indicating a build-out phase [New Wave Biotech, retrieved 2026]. Translating academic-grade models into reliable, user-friendly enterprise software will require deep bench strength in both domains.
The next twelve months
With its seed capital secured, New Wave's immediate roadmap likely involves both product hardening and commercial outreach. Key milestones to watch will be the announcement of paid commercial customers beyond early accelerator partners and the publication of more detailed, peer-adjacent case studies. The company's participation in programs like the Tech Nation Climate Programme and the EIT Food Accelerator Network provides a pipeline of potential early adopters in the alt-protein sector [Tech Nation Climate Programme]. Success will be measured not by simulation accuracy alone, but by the platform's ability to become a non-negotiable tool in the tech transfer process from pilot plant to full-scale factory. For an industry racing to reach cost parity with incumbent products, shaving months off development timelines could be the decisive edge.
Sources
- [New Wave Biotech, retrieved 2026] DSP Decision Intelligence for Biomanufacturing | https://www.newwavebiotech.com/
- [EU-Startups, Dec 2024] New Wave Biotech raises €1.2 million to transform R&D in synbio and alt protein production | https://www.eu-startups.com/2024/12/new-wave-biotech-raises-e1-2-million-to-transform-rd-in-synbio-and-alt-protein-production/
- [Tracxn, retrieved 2026] New Wave Biotech - Funding Rounds & Investors | https://tracxn.com/d/companies/newwavebiotech/__OKBHRFEwTp9ohwhAPMkNML6Oq6BcrW7hj34qc9WAnvE/funding-and-investors
- [Crunchbase, Oct 2024] New Wave Biotech - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/new-wave-biotech
- [Green Queen, retrieved 2026] New Wave Biotech Secures €1.2 Million in Latest Funding Round | https://cultivated-x.com/investments-finance/new-wave-biotech-secures-e1-2-million-latest-funding-round-expand-ai-bioprocess-simulation-platform/
- [The Org, retrieved 2026] New Wave Biotech Company Profile | https://theorg.com/company/new-wave-biotech
- [Tech Nation Climate Programme] Accelerator Program for Climate Tech Companies